Addition Technology Receives Authorization to Expand
INTACS™ Prescription Inserts Range in Europe
Fremont, California, November 19, 2002 – Addition Technology, Inc., the maker of INTACS prescription inserts for surgical vision correction, announced today that it has received a CE marking for six additional ICRS (Intrastromal Corneal Ring Segments) sizes, thereby doubling its product line in Europe.
“The expanded range of treatment options will address the vision correction needs of 70 percent of myopia patients, affording European surgeons even more flexibility to refine their treatment of myopia,” said William M. Flynn, president and chief executive officer of Addition Technology.
In response to European surgeons’ requests, these new sizes of INTACS inserts expand Intacs treatment range to -0.50 to -5.00D, and also provide both smaller increments of correction (0.210mm, 0.230mm, 0.275mm, 0.325mm, 0.375mm, and 0.425mm) within that range.
With these new insert sizes, INTACS inserts are now approved in Europe for patients with -0.50D to -5.00D of myopia and 1.00D or less of astigmatism. Addition Technology is currently conducting studies in Europe using INTACS inserts for the treatment of hyperopia, keratoconus and myopia with greater than 1.00D of astigmatism.
In the United States, INTACS inserts are approved now for -1.00D to -3.00D with 1.00D or less of astigmatism.
Addition Technology, Inc. manufactures INTACS prescription inserts, the only additive refractive corneal implant approved by the U.S. Food and Drug Administration.
